Literature DB >> 62162

Low renin hypertension. A distinct entity.

H Thurston, J D Swales.   

Abstract

In an attempt to resolve conflicting reports about the identity of a low-renin subgroup in essential hypertension, the distribution of plasma-renin activity (P.R.A.) has been examined in 82 hypertensive subjects before and after stimulation with bendrofluazide. The unstimulated basal P.R.A. showed no evidence of a separate subgroup of patients with low P.R.A. values although the distribution was slightly skewed with a tail to the right when compared with 83 normotensive subjects. In 38 of the patients post-stimulation P.R.A. observed in age and sex matched normotensive controls exposed to the same stimulus. However the percentage rise in P.R.A. in all 83 patients was less than half that of the controls. Thus the identification of a low-renin subgroup of hypertensive patients is critically determined by the standard of comparison employed: if the percentage rise is considered subnormal responsiveness is a feature of essential hypertension. If absolute post-stimulation values are used, there is a substantial group of patients with "low renin hypertension". The demarcation of such a group is, however, essentially arbitrary.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62162     DOI: 10.1016/s0140-6736(76)90892-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  Which drug for hypertension?

Authors: 
Journal:  Br Med J       Date:  1978-07-08

2.  Primary aldosteronism: how hard should we look?

Authors:  J D Swales
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-10

Review 3.  Blood pressure and the kidney.

Authors:  J D Swales
Journal:  J Clin Pathol       Date:  1981-11       Impact factor: 3.411

4.  Age- and sex-related differences in plasma aldosterone in essential hypertension. Relationship to plasma renin activity.

Authors:  H Vetter; K Glänzer; I Alasso; W Vetter
Journal:  Klin Wochenschr       Date:  1979-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.